Bio Green Med Solution, Inc.
BGMS Healthcare Biotechnology
Bio Green Med Solution, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747,000.00, up 1,637.2% from fiscal 2024. In the quarter to June 2026, revenue grew 3,260.0%, EPS grew 91.8% and free cash flow grew 66.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BGMS
Bio Green Med Solution, Inc. (BGMS) P/E ratio
Bio Green Med Solution, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 14 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| ORGS Orgenesis Inc. compare | n/m |
| CANF Can-Fite Biopharma Ltd compare | n/m |
| BGMS Bio Green Med Solution, Inc. | n/m |
| IMNN Imunon, Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)